R P Smith

STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and pote…

Primary dysmenorrhea, secondary dysmenorrhea, and cyclic pelvic pain syndromes represent a special subset of CPP. Although more common and no less debilitating, these conditions are better understood, more easily diagnosed, and more success…

Assessment of cases of chronic pelvic pain presents a challenging problem, and many physicians overlook the association of sleep disorders and depression with such pain. We examined these linkages in our chronic pelvic pain clinic, using a …

Very few attempts to describe, codify , and implement analysis of intrauterine pressure data have occurred in the past. With a growing interest in intrauterine pressure during dysmenorrhea, the need for new ways of evaluating pressure data …

This symposium reviewed current knowledge about the treatment of menorrhagia or excessive menstrual bleeding. In the absence of an organic cause medical treatment is preferred over surgical treatment especially if the patient desires future…